search
Back to results

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

Primary Purpose

Extracorporeal Membrane Oxygenation

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Hydromorphone
Sponsored by
Xiaobo Yang, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Extracorporeal Membrane Oxygenation focused on measuring Extracorporeal Membrane Oxygenation, Pharmacokinetics, Hydromorphone

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Between the ages of 18 and 70;
  • Using hydromorphone for pain relief;
  • Using ECMO for more than 96h

Exclusion Criteria:

  • Allergic to hydromorphone;
  • Use of CRRT during ECMO;
  • Liver function Child-Pugh B, C grade;
  • Pregnancy;
  • Intestinal obstruction;
  • Refused to sign the informed consent.

Sites / Locations

  • Wuhan Union HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Hydromorphone

Arm Description

Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.

Outcomes

Primary Outcome Measures

Volume of distribution of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO
Quantitative liquid chromatography-tandem mass spectrometry was used to detect the contents of hydromorphone and hydromorphone -3- glucuronide in blood samples at various time points, so as to obtain the pharmacokinetics of continuous intravenous infusion of hydromorphone for 72 hours during ECMO.

Secondary Outcome Measures

Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO
Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO

Full Information

First Posted
September 13, 2022
Last Updated
August 27, 2023
Sponsor
Xiaobo Yang, MD
search

1. Study Identification

Unique Protocol Identification Number
NCT05565495
Brief Title
The Effects of ECMO on the Pharmacokinetics of Hydromorphone
Official Title
The Effects of ECMO on the Pharmacokinetics of Hydromorphone
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xiaobo Yang, MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.
Detailed Description
A population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO was established. The patients were given hydromorphone 0.03mg/kg/h by continuous intravenous infusion for 72 hours for analgesia. Blood samples were collected at different time points before and after administration, and quantitative liquid chromatography tandem mass spectrometry was used to detect hydromorphone and its main metabolite, hydromorphone-3-glucuronide.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Extracorporeal Membrane Oxygenation
Keywords
Extracorporeal Membrane Oxygenation, Pharmacokinetics, Hydromorphone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hydromorphone
Arm Type
Experimental
Arm Description
Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Intervention Type
Drug
Intervention Name(s)
Hydromorphone
Intervention Description
Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Primary Outcome Measure Information:
Title
Volume of distribution of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO
Description
Quantitative liquid chromatography-tandem mass spectrometry was used to detect the contents of hydromorphone and hydromorphone -3- glucuronide in blood samples at various time points, so as to obtain the pharmacokinetics of continuous intravenous infusion of hydromorphone for 72 hours during ECMO.
Time Frame
Within 4 days
Secondary Outcome Measure Information:
Title
Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO
Description
Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO
Time Frame
Within 4 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Between the ages of 18 and 80; Using hydromorphone for pain relief; Using ECMO for more than 96h Exclusion Criteria: Allergic to hydromorphone; Use of CRRT during ECMO; Liver function Child-Pugh B, C grade; Pregnancy; Intestinal obstruction; Refused to sign the informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
You Shang, Prof.
Phone
008602785351607
Email
you_shanghust@163.com
Facility Information:
Facility Name
Wuhan Union Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
You Shang
Phone
15972127819
Email
you_shanghust@163.com

12. IPD Sharing Statement

Learn more about this trial

The Effects of ECMO on the Pharmacokinetics of Hydromorphone

We'll reach out to this number within 24 hrs